Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

OBJECTIVE: Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-loweri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajaj, Harpreet S., Bergenstal, Richard M., Christoffersen, Andreas, Davies, Melanie J., Gowda, Amoolya, Isendahl, Joakim, Lingvay, Ildiko, Senior, Peter A., Silver, Robert J., Trevisan, Roberto, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323191/
https://www.ncbi.nlm.nih.gov/pubmed/33875485
http://dx.doi.org/10.2337/dc20-2877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323191/
https://www.ncbi.nlm.nih.gov/pubmed/33875485
http://dx.doi.org/10.2337/dc20-2877

Ejemplares similares